2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3262 Combined menin and XPO1 inhibition show synergy in UBTF tandem duplication mutated acute myeloid leukemias.

Juan Martìn Barajas, PhD, Lisett Contreras, PhD2, Josi Lott, BS3, Haley Writt4, Chandra Rolle5, Jamila Moore6, Dixie Brewington7, Sandi Radko-Juettner, PhD8, Hasan Reza9, Ayush Attery10, Anang A. Shelat11, Jing Ma, PhD12, Laura Janke13, Jeffery M. Klco, Member; Director, Division of Hematopathology and Molecular Pathology14
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Tandem duplications in UBTF have emerged as a subtype-defining mutation in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).  First identified as a recurrent alteration in ~4% of primary de novo pediatric AML and nearly 10% of relapsed pediatric AML, UBTF-TD myeloid neoplasms are now recognized as an enriched entity in adolescents and young adults.  Patients with myeloid neoplasms driven by these in-frame somatic mutations typically demonstrate a poor response to conventional therapy and are associated with high rates of MRD positivity and relapse, underscoring the need for better therapeutic options for these patients. This work addresses this therapeutic gap by evaluating XPO1 and menin inhibitor combination therapy. 

To identify therapeutic dependencies in UBTF-TD AML, we generated a murine UBTF-TD84 cell line (mELT84) that recapitulated the transcriptional and immunophenotypic features of UBTF-TD patient samples. A custom CRISPR-knockout screen (210 genes, 1,386 sgRNAs) identified Polr1b, Kmt2a, Xpo1, Men1, Ranbp2, Meis1, and Hoxa9 as top dependencies. Given the availability of clinical-grade inhibitors, we focused on Xpo1 and Men1, targeting them with the XPO1 inhibitor eltanexor and the menin inhibitor revumenib. In a colony-forming unit (CFU) assay, single-agent and combination treatment of murine mELT84 cells reduced colony-forming potential, with combination treatment producing the greatest suppression of colony formation.  This correlated with increased differentiation as measured by flow cytometry and a decrease of Hox cluster gene expression. Furthermore, eltanexor and revumenib showed synergy in human UBTF-TD84 and UBTF-TD54 CD34+ cells and in UBTF-TD patient-derived xenograft (PDX) cells.

 In a luciferase-positive UBTF-TD PDX model, combination therapy significantly reduced leukemic burden, with decreased human CD45+ cells in the peripheral blood and spleen, reduced spleen weight, and decreased bioluminescence signal relative to vehicle and single-agent arms. In an independent survival study, combination therapy produced the most robust extension in survival among all treatment arms. Human cells obtained from the bone marrow of single-agent and combination-treated mice showed reduced colony-forming capacity, and single-cell RNA-sequencing revealed a shift from immature HSPC/GMP populations toward differentiated monocyte and granulocyte populations, with decreased expression of stem/progenitor genes (KIT, HOXA9, CD34) and increased expression of differentiation genes (MPO, S100A9, LYZ).

 These studies identify combined XPO1 and menin inhibition as an effective therapeutic strategy for UBTF-TD AML. This builds on previous work that identified XPO1 and menin as key regulators of UBTF-TD biology, supported by evidence from murine models, human cellular models, and a PDX model. Together, these findings address a critical gap in the treatment of UBTF-TD myeloid neoplasms and support clinical evaluation of eltanexor and revumenib combination therapy for children and young adults with this high-risk AML subtype.

Juan Martìn Barajas, PhD: No relevant conflicts of interest to declare.